Market Launch of New Granulation Unit Hüttlin GranuLean
At Achema 2015, Bosch Packaging Technology presents the new granulation unit GranuLean for the first time. Developed by the Bosch subsidiary Hüttlin GmbH, it combines the process steps of mixing, granulating and drying for the manufacturing of pharmaceutical granules. “The name GranuLean stands for a lean and compact machine, which can be easily integrated into production rooms and focuses on the basic requirements of pharmaceutical producers,” Fritz-Martin Scholz, product manager at Bosch Packaging Technology, explains. “By concentrating on the essential basic functions within fixed dimensions, we have developed an especially efficient granulation solution.” The GranuLean exhibited at Achema for instance saves valuable production room with its 6 m length and 3.4 m height. The new development is available for three different batch sizes and is based on Hüttlin’s long-standing process technology experience.
Simplified Construction, Uniform Human Machine Interface
As opposed to tailor-made granulation lines, the most important functions of GranuLean are installed by default. “The high level of standardization now enables us to fulfill customer demands for a complete and quickly available system at the accustomed high quality,” says Scholz. Thanks to the easy alignment of machine components on site, the granulation unit can be installed quickly and easily. All process and cleaning steps can be controlled via recipes. The operator interface is a 21-inch touchscreen with user-friendly navigation.
Smooth Product Flow Through Integrated Wet Mill
The process for manufacturing pharmaceutical granules begins by pneumatically filling the high-shear mixer. The mixing device Gentlewing, which is driven from below, mixes and granulates the active ingredients and excipients. The highshear mixer is emptied via the equally newly developed, integrated wet mill.
Communication between mill and Gentlewing ensures that only as much product is emptied as the mill is able to process, which prevents the mill from clogging. A pneumatic transfer pipe subsequently transfers the wet product to the GranuLean fluid bed module, where it is dried through the inflow of the proven Diskjet
distribution plate. The function of process filters is crucial to obtain high yields: for this reason, Bosch has developed a new process filter, where the elements are serially cleaned with compressed air pulses. At the end of the drying process, the product is emptied by a dry mill.
Apart from the high-shear mixer, granulation can also take place in the fluid bed by using a tangential or top spray process. GranuLean is available for a containment level of up to OEB3 (Operational Exposure Band). The machine remains closed during operation, while inflatable seals on the product containers provide for an optimum draughtproofing. Moreover, the integrated cleaning system ensures an even easier handling.
Tablets and Capsules In lLne
Suitable handling equipment makes it possible to combine the new granulation unit to a compact line, for instance with the new tablet presses of the Manesty TPR range. Alternatively, the granule can be filled into stick packs or capsules, for example with the new GKF 2600 capsule filling machine from Bosch.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance